Abstrakt

Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the main reasons of severe pulmonary hypertension and has significantly higher morbidity and mortality rates. The pathogenesis of the disease is characterized by the incomplete resolution of acute embolisms. The elevated inflammatory conditions after the acute embolism are one of the critical factors. Therefore, we aimed to investigate whether or not anakinra is an option for treating CTEPH in an animal model. We studied twenty-one rats in this study They were randomly divided into three groups containing seven animals: the control group: saline-treated control; the embolism group: CTEPH + normal saline; the anakinra group: CTEPH + anakinra. We have observed that the layers of the segmental arteries and the alveolar were normal in the control group. In the cardiac tissue it was observed that muscular tissues and connective tissue were normal in the right ventricle. In embolism group, we detected a widening of the alveolar septum, a surrounding the alveolar infiltrates and a thickening of the segmental arteries in the muscular layer and a hypertrophy in the right ventricle tissues. We have determined that the lung and cardiac tissue specimens in the anakinra group are similar to control group. We have showed that anakinra was useful option for the CTEPH model in rats. Anakinra may be considered as protective effect and the regression of the increased inflammation in CTEPH. The effectiveness of anakinra will continue to be subject to the further experimental and clinical studies.

Przypisy

• 1. Abramson S.B., Amin A.: Blocking the effects of IL-1 in rheumatoidarthritis protects bone and cartilage. Rheumatology, 2002; 41: 972-980
  Google Scholar
• 2. Bilginer Y., Ayaz N.A., Ozen S.: Anti-IL-1 treatment for secondaryamyloidosis in an adolescent with FMF and Behçet’s disease. Clin.Rheumatol., 2010; 29: 209-210
  Google Scholar
• 3. Blauwet L.A., Edwards W.D., Tazelaar H.D., McGregor C.G.: Surgicalpathology of pulmonary thromboendarterectomy: a study of 54cases from 1990 to 2001. Hum Pathol., 2003; 34: 1290-1298
  Google Scholar
• 4. Bonderman D., Jakowitsch J., Redwan B., Bergmeister H., RennerM.K., Panzenböck H., Adlbrecht C., Georgopoulos A., Klepetko W.,Kneussl M., Lang I.M.: Role for staphylococci in misguided thrombusresolution of chronic thromboembolic pulmonary hypertension.Arterioscler. Thromb. Vasc. Biol., 2008; 28: 678-684
  Google Scholar
• 5. Bonderman D., Turecek P.L., Jakowitsch J., Weltermann A., AdlbrechtC., Schneider B., Kneussl M., Rubin L.J., Kyrle P.A., KlepetkoW., Maurer G., Lang I.M.: High prevalence of elevated clotting factorVIII in chronic thromboembolic pulmonary hypertension. Thromb.Haemost., 2003; 90: 372-376
  Google Scholar
• 6. Bonderman D., Wilkens H., Wakounig S., Schäfers H.J., Jansa P.,Lindner J., Simkova I., Martischnig A.M., Dudczak J., Sadushi R., Skoro-Sajer N., Klepetko W., Lang I.M.: Risk factors for chronic thromboembolicpulmonary hypertension. Eur. Respir. J., 2009; 33: 325-331
  Google Scholar
• 7. Burgy O., Bellaye P.S., Causse S., Beltramo G., Wettstein G., BoutanquoiP.M., Goirand F., Garrido C., Bonniaud P.: Pleural inhibitionof the caspase-1/IL-1β pathway diminishes profibrotic lung toxicityof bleomycin. Respir Res., 2016; 17: 162
  Google Scholar
• 8. Campos M., Schiopu E.: Pulmonary arterial hypertension in adult–onset Still’s disease: Rapid response to anakinra. Case Rep. Rheumatol.,2012; 2012: 537613
  Google Scholar
• 9. Deng C., Wu D., Zhai Z., Lin Q., Zhong Z., Yang Y., Chen Q., Lian N.,Gao S., Yang M., Liu K., Wang C.: Close concordance between pulmonaryangiography and pathology in a canine model with chronic pulmonarythromboembolism and pathological mechanisms after lung ischemiareperfusion injury. J. Thromb. Thrombolysis, 2016; 41: 581-591
  Google Scholar
• 10. Dinarello C.A., Simon A., van der Meer J.W.: Treating inflammationby blocking interleukin-1 in a broad spectrum of diseases. Nat.Rev. Drug Discov., 2012; 11: 633-652
  Google Scholar
• 11. Fedullo P., Kerr K.M., Kim N.H., Auger W.R.: Chronic thromboembolicpulmonary hypertension. Am. J. Respir. Crit. Care Med.,2011; 1830: 1605-1613
  Google Scholar
• 12. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., Dinarello C.A.: Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum., 2005; 52: 1794–1803
  Google Scholar
• 13. Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Gho­frani A., Gomez Sanchez M.A., Hansmann G., Klepetko W., Lancellotti P., et al.: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Socie­ty of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Trans­plantation (ISHLT). Eur. Heart J., 2016; 37: 67–119
  Google Scholar
• 14. Ghofrani H.A., D’Armini A.M., Grimminger F., Hoeper M.M., Jansa P., Kim N.H., Mayer E., Simonneau G., Wilkins M.R., Fritsch A., Neuser D., Weimann G., Wang C., CHEST-1 Study Group: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med., 2013; 369: 319–329
  Google Scholar
• 15. Ghofrani H.A., Simonneau G., D’Armini A.M., Fedullo P., Howard L.S., Jaïs X., Jenkins D.P., Jing Z.C., Madani M.M., Martin N., Mayer E., Papadakis K., Richard D., Kim N.H., MERIT Study Investigators: Ma­citentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med., 2017; 5: 785–794
  Google Scholar
• 16. Guihaire J., Haddad F., Boulate D., Capderou A., Decante B., Flécher E., Eddahibi S., Dorfmüller P., Hervé P., Humbert M., Ver­hoye J.P., Dartevelle P., Mercier O., Fadel E.: Right ventricular plasti­city in a porcine model of chronic pressure overload. J. Heart Lung Transplant., 2014; 33: 194–202
  Google Scholar
• 17. Homoncik M., Gessl A., Ferlitsch A., Jilma B., Vierhapper H.: Al­tered platelet plug formation in hyperthyroidism and hypothyro­idism. J. Clin. Endocrinol. Metab., 2007; 92: 3006–3012
  Google Scholar
• 18. Iannitti R.G., Napolioni V., Oikonomou V., De Luca A., Galosi C., Pariano M., Massi-Benedetti C., Borghi M., Puccetti M., Lucidi V., Co­lombo C., Fiscarelli E., Lass-Flörl C., Majo F., Cariani L., et al.: IL-1 recep­tor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat. Commun., 2016; 7: 10791
  Google Scholar
• 19. Jaïs X., D’Armini A.M., Jansa P., Torbicki A., Delcroix M., Ghofrani H.A., Hoeper M.M., Lang I.M., Mayer E., Pepke-Zaba J., Perchenet L., Morganti A., Simonneau G., Rubin L.J., Bosentan Effects in iNopE­rable Forms of chronIc Thromboembolic pulmonary hypertension Study Group: Bosentan for treatment of inoperable chronic throm­boembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hyper­tension), a randomized, placebo-controlled trial. J. Am. Coll. Cardiol,. 2008; 52: 2127–2134
  Google Scholar
• 20. Kellermair J., Redwan B., Alias S., Jabkowski J., Panzenboeck A., Kellermair L., Winter M.P., Weltermann A., Lang I.M.: Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution. Blood, 2013; 122: 3376–3384
  Google Scholar
• 21. Lang I.M., Dorfmüller P., Vonk Noordegraaf A.: The pathobiolo­gy of chronic thromboembolic pulmonary hypertension. Ann. Am. Thorac. Soc., 2016; 13: S215–S221
  Google Scholar
• 22. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T.: Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care, 2009; 32: 1663–1668
  Google Scholar
• 23. Li C.Y., Deng W., Liao X.Q., Deng J., Zhang Y.K., Wang D.X.: The effects and mechanism of ginsenoside Rg1 on myocardial remo­deling in an animal model of chronic thromboembolic pulmonary hypertension. Eur. J. Med. Res., 2013; 18: 16
  Google Scholar
• 24. Mercier O., Arthur Ataam J., Langer N.B., Dorfmüller P., Lamrani L., Lecerf F., Decante B., Dartevelle P., Eddahibi S., Fadel E.: Abnormal pulmonary endothelial cells may underlie the enigmatic pathoge­nesis of chronic thromboembolic pulmonary hypertension. J. Heart Lung Transplant., 2017; 36: 305–314
  Google Scholar
• 25. Moser K.M., Cantor J.P., Olman M., Villespin I., Graif J.L., Konopka R., Marsh J.J., Pedersen C.: Chronic pulmonary thromboembolism in dogs treated with tranexamic acid. Circulation, 1991; 83: 1371–1379
  Google Scholar
• 26. Pepke-Zaba J., Delcroix M., Lang I., Mayer E., Jansa P., Ambroz D., Treacy C., D’Armini A.M., Morsolini M., Snijder R., Bresser P., Torbicki A., Kristensen B., Lewczuk J., Simkova I., et al.: Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation, 2011; 124: 1973–1981
  Google Scholar
• 27. Quarck R., Nawrot T., Meyns B., Delcroix M.: C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hyper­tension. J. Am. Coll. Cardiol., 2009; 53: 1211–1218
  Google Scholar
• 28. Scannapieco F.A., Ng P., Hovey K., Hausmann E., Hutson A., Wac­tawski-Wende J.: Salivary biomarkers associated with alveolar bone loss. Ann. N. Y. Acad. Sci., 2007; 1098: 496–497
  Google Scholar
• 29. Simonneau G., Gatzoulis M.A., Adatia I., Celermajer D., Denton C., Ghofrani A., Gomez Sanchez M.A., Krishna Kumar R., Landzberg M., Machado R.F., Olschewski H., Robbins I.M., Souza R.: Updated clinical classification of pulmonary hypertension. J. Am. Coll. Car­diol., 2013; 62: D34–D41
  Google Scholar
• 30. Soon E., Holmes A.M., Treacy C.M., Doughty N.J., Southgate L., Machado R.D., Trembath R.C., Jennings S., Barker L., Nicklin P., Walker C., Budd D.C., Pepke-Zaba J., Morrell N.W.: Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation, 2010; 122: 920–927
  Google Scholar
• 31. Svensson S., Forsberg M., Hulander M., Vazirisani F., Palmquist A., Lausmaa J., Thomsen P., Trobos M.: Role of nanostructured gold surfaces on monocyte activation and Staphylococcus epidermidis bio­film formation. Int. J. Nanomedicine, 2014; 9: 775–794
  Google Scholar
• 32. Wolf M., Boyer-Neumann C., Parent F., Eschwege V., Jaillet H., Meyer D., Simonneau G.: Thrombotic risk factors in pulmonary hy­pertension. Eur. Respir. J,. 2000; 15: 395–399
  Google Scholar
• 33. Yao W., Firth A.L., Sacks R.S., Ogawa A., Auger W.R., Fedullo P.F., Madani M.M., Lin G.Y., Sakakibara N., Thistlethwaite P.A., Jamieson S.W., Rubin L.J., Yuan J.X.: Identification of putative endothelial pro­genitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of pa­tients with chronic thromboembolic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol., 2009; 296: L870–L878
  Google Scholar
• 34. Zabini D., Nagaraj C., Stacher E., Lang I.M., Nierlich P., KlepetkoW., Heinemann A., Olschewski H., Bálint Z., Olschewski A.: Angiostaticfactors in the pulmonary endarterectomy material from chronicthromboembolic pulmonary hypertension patients cause endothelialdysfunction. PLoS One, 2012; 7: e43793
  Google Scholar

Pełna treść artykułu